Review finds timing of aneurysm repair and recovery remains uncertain
Earlier repair was associated with less bleeding before treatment, but links with death or disability were not consistent.
Very low evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers searched three medical databases for studies comparing outcomes across different times from symptom onset to aneurysm treatment. They synthesized the findings narratively rather than combining them in a formal statistical meta-analysis. Treatment times ranged from less than 6 hours to 15 days or more.
Earlier securement appeared to reduce pretreatment rebleeding, especially when untreated or substantially delayed patients were included. However, comparisons among patients who all received treatment were inconsistent, and adjusted analyses did not show a reproducible independent association between treatment timing and functional outcome or mortality. Findings were also inconsistent for vasospasm, related brain ischemia, hydrocephalus, and hospital length of stay.
The question reviewed
The researchers conducted a systematic review of studies involving adults with confirmed aneurysmal subarachnoid hemorrhage. They searched PubMed/MEDLINE, Scopus, and LILACS and included 20 reports covering 11,096 participant records, although two reports may have included overlapping participants. The review compared outcomes across different intervals from bleeding onset to aneurysm securement and examined whether the treatment method changed these associations. Findings were synthesized according to the Synthesis Without Meta-analysis guideline.
Key conclusions
Earlier aneurysm securement likely reduced the chance of rebleeding before treatment, particularly in analyses that included untreated or markedly delayed cases. Among treated patients, however, the findings were inconsistent. More informative adjusted analyses found no reproducible independent association between treatment timing and functional outcome or mortality, and no consistent association with vasospasm or related cerebral ischemia, hydrocephalus, or length of stay.
Two observational studies modeled treatment time as a continuous measure and reported similar U-shaped mortality patterns, but one was statistically significant, with an estimated lowest-risk point at 32.6 hours, while the other was not significant and estimated a point near 12.16 hours. These patterns may reflect confounding by indication and survivor bias rather than an effect of delaying treatment. Only one of three studies that tested whether treatment method altered the timing–mortality association found a significant interaction. The review states that these results are hypothesis-generating and do not define a validated treatment window or support intentional delay.
Where this may apply
These findings may apply most closely to adults with confirmed aneurysmal subarachnoid hemorrhage treated in settings similar to those represented in the included studies. They do not establish that any particular treatment timing is appropriate for an individual patient, and they do not support intentional treatment delay. The review does not directly address children, people with other causes of bleeding around the brain, or patient groups and care settings not represented in the included reports.
What this could mean
Aneurysmal subarachnoid hemorrhage is a serious human medical emergency, so understanding treatment timing is clinically important. This review supports the concern that leaving an aneurysm unsecured can be associated with rebleeding before treatment, but it does not show that a particular delay improves survival or recovery. The findings do not establish a reason to change current guideline recommendations.
Limitations & evidence assessment
The evidence was mainly observational, so differences in patient severity, treatment decisions, and survival until treatment could have influenced the results. The authors specifically identified confounding by indication and survivor bias, as well as serious risk of bias, inconsistency, and imprecision; the two continuous-time studies also produced different estimates. The review used a narrative synthesis, treatment-time categories varied widely, and two reports may have included overlapping participants. The abstract provides limited information about the individual studies, including their follow-up periods and detailed methods, so the reliability of comparisons across studies is difficult to judge.
Why this evidence level: The review included many participant records, but the abstract reports very low certainty for the key timing–mortality association. Most evidence was observational and affected by serious risk of bias, inconsistent findings, possible survivor bias, confounding, and imprecision.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Journal of Neurology · 2026 · DOI: 10.1007/s00415-026-14063-x
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
